The Journal of dermatological treatment最新文献_第10页

Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study. 口服罗氟司特治疗牛皮癣：一项现实世界24周的前瞻性队列研究

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-11 DOI: 10.1080/09546634.2025.2464107

Ana Maria Lé, Orhan Yilmaz, Martim Luz, Tiago Torres

{"title":"Oral roflumilast for psoriasis: a real-world 24-week prospective cohort study.","authors":"Ana Maria Lé, Orhan Yilmaz, Martim Luz, Tiago Torres","doi":"10.1080/09546634.2025.2464107","DOIUrl":"10.1080/09546634.2025.2464107","url":null,"abstract":"Objective: Psoriasis is a chronic inflammatory skin disease with significant physical and psychological burden, often associated with comorbidities such as obesity and cardiovascular disease. Current treatments include conventional systemic therapies and targeted biologic and non-biologic therapies, with several limitations related to safety, efficacy, and cost. Roflumilast, a selective PDE4 inhibitor, shows potential as an oral therapy for psoriasis due to its anti-inflammatory effects and favorable safety profile. This study aimed to evaluate the real-world effectiveness and safety of oral roflumilast in moderate-to-severe plaque psoriasis.Methods: Prospective cohort study at a single center in Portugal including adults with moderate-to-severe psoriasis treated with oral roflumilast 500 mcg once daily.Results: Among fifty-eight patients (baseline median PASI 13.7 ± 5.5), 63.0% achieved PASI < 5, 47.8% PASI < 3, and 21.7% PASI < 1 by week 24 (mNRI). Weight loss occurred in 53.4%, with a mean reduction of 6 kg ± 4.3. Mild gastrointestinal symptoms were common but rarely caused discontinuation. No serious adverse events were reported.Conclusion: Roflumilast demonstrated real-world effectiveness and a favorable safety profile in moderate-to-severe plaque psoriasis. Additional benefits, including weight loss and no need for laboratory monitoring, make it a promising treatment option, particularly for patients with comorbidities or limited access to biologic therapies.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2464107"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143401075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicenter pilot study of the effectiveness and safety of a monopolar radiofrequency device for improving periorbital and facial fine wrinkles. 单极射频设备改善眶周和面部细小皱纹的有效性和安全性的多中心试点研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-03-11 DOI: 10.1080/09546634.2025.2469633

Hee Joo Yang, Sun Young Choi, Joon Min Jung, Yoon-Seo Jo, Hye Sung Han, Young In Lee, Ju Hee Lee, Chong Hyun Won

{"title":"A multicenter pilot study of the effectiveness and safety of a monopolar radiofrequency device for improving periorbital and facial fine wrinkles.","authors":"Hee Joo Yang, Sun Young Choi, Joon Min Jung, Yoon-Seo Jo, Hye Sung Han, Young In Lee, Ju Hee Lee, Chong Hyun Won","doi":"10.1080/09546634.2025.2469633","DOIUrl":"10.1080/09546634.2025.2469633","url":null,"abstract":"Purpose: This study aimed to investigate the effectiveness and safety of a new monopolar radiofrequency device equipped with a 5 cm2 tip, against fine wrinkles around the eyes and cheeks.Materials and methods: This multicentered, prospective pilot study involved treating participants with mild-to-moderate wrinkles on both periorbital areas and cheeks using the monopolar radiofrequency device for one session. One and four months after treatment, wrinkle reduction, overall esthetic improvement, adverse events, and vital signs were evaluated.Results: The study involved 13 participants (age: 35-62 years) and on a five-point scale, periorbital wrinkles showed a significant reduction at 4 weeks (0.96 ± 0.65) and 16 weeks (1.04 ± 0.59). On a five-point scale, cheek wrinkles also decreased at weeks 4 and 16 (1.00 ± 0.55 and 1.12 ± 0.64, respectively). On a five-point scale (range: -1-3), overall global esthetic improvement was rated by the participants at weeks 4 and 16 to be 2.23 ± 0.80 and 2.31 ± 0.61, respectively. Adverse events were not observed during the follow-up.Conclusion: A single session using the new monopolar radiofrequency device equipped with a 5 cm2 tip safely and effectively improves mild-to-moderate periorbital and facial wrinkles.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2469633"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 对Stevens-Johnson综合征和中毒性表皮坏死松解患者的临床实践指南进行系统回顾、方法学评估和推荐。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-02-26 DOI: 10.1080/09546634.2025.2467751

Mohammed AlFada, Hend Alotaibi, Sahar Alsharif, Ahmad Hecham Alani, Andrea Andrade-Miranda, Camila Montesinos Guevara, Yaolong Chen, Ruobing Lei, Jorge Acosta-Reyes, Pamela Velásquez-Salazar, Ahmed El-Malky, Yasser S Amer

{"title":"Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.","authors":"Mohammed AlFada, Hend Alotaibi, Sahar Alsharif, Ahmad Hecham Alani, Andrea Andrade-Miranda, Camila Montesinos Guevara, Yaolong Chen, Ruobing Lei, Jorge Acosta-Reyes, Pamela Velásquez-Salazar, Ahmed El-Malky, Yasser S Amer","doi":"10.1080/09546634.2025.2467751","DOIUrl":"10.1080/09546634.2025.2467751","url":null,"abstract":"Purpose: The Appraisal of Guidelines for Research and Evaluation II Instrument (AGREE II) was developed to enhance the methodological rigor of clinical practice guidelines (CPGs), aiming to generate trustworthy recommendations for various clinical scenarios. Despite its importance, there exists a gap in the quality of CPGs pertaining to Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS-TEN). The aim of the study was to evaluate SJS-TEN CPGs to shed light on areas for enhancing SJS-TEN guidelines' quality.Materials and methods: A systematic review was conducted to identify SJS-TEN CPGs from January 2011 to December 2023 across bibliographic and guideline databases, as well as dermatology association websites. Four reviewers employed the AGREE II instrument to appraise the quality of eligible CPGs. Subsequently, AGREE II domain scores were calculated and their recommendations mapped.Results and conclusions: Seven eligible SJS-TEN CPGs reviewed, originating from Europe, North America, Asia, and an authorship Group. The highest AGREE II domain scores were observed in scope and purpose (mean: 63%, standard deviation [SD]: 23.195%) and clarity of presentation (mean: 70%, SD: 14.5%). Conversely, the lowest score was noted in the applicability domain (mean: 28%, SD: 17.44%). Only two guidelines by the British Association of Dermatologists (28.6%) met the 'recommend' level. Recommendations from all CPGs were compared in tabular form.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2467751"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study. 靶向窄带紫外B、308 nm准分子激光和308 nm准分子灯治疗白癜风的疗效和安全性比较：回顾性研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-17 DOI: 10.1080/09546634.2025.2514637

Thamonwan Tantivithiwate, Chayada Chaiyabutr, Chanisada Wongpraparut, Punyanut Yothachai, Nuttaporn Nuntawisuttiwong, Narumol Silpa-Archa

{"title":"Comparative efficacy and safety of targeted narrowband ultraviolet B, 308-nm excimer laser, and 308-nm excimer lamp in vitiligo: a retrospective study.","authors":"Thamonwan Tantivithiwate, Chayada Chaiyabutr, Chanisada Wongpraparut, Punyanut Yothachai, Nuttaporn Nuntawisuttiwong, Narumol Silpa-Archa","doi":"10.1080/09546634.2025.2514637","DOIUrl":"https://doi.org/10.1080/09546634.2025.2514637","url":null,"abstract":"Background: Data directly comparing targeted narrowband ultraviolet B (NB-UVB), 308-nm excimer laser, and 308-nm excimer lamp for vitiligo are limited.Objectives: We compared the efficacy and safety of these three modalities in vitiligo.Methods: In this retrospective study, we reviewed the medical records of vitiligo patients at the Photodermatology Clinic, Siriraj Hospital. Patients received either targeted NB-UVB (group A), a 308-nm excimer laser (group B), or a 308-nm excimer lamp (group C), administered two to three times per week for at least 3 months. Photographs taken before and after therapy were evaluated. The primary outcome was repigmentation, graded on a five-tier scale: poor (0-25%), fair (26-50%), good (51-75%), very good (76-90%), and excellent (91-100%). The secondary outcome was treatment-related adverse events.Results: No statistically significant differences in efficacy were observed among the three groups, indicated by a very good to excellent response in 42.4% (group A), 17.6% (group B), and 29.4% (group C). Although group A showed higher response rates at 3 and 6 months, differences were not significant. Adverse effects were significantly more frequent in group C.Conclusions: All three devices demonstrated comparable efficacy and promoted rapid repigmentation. However, the excimer lamp had the highest rate of adverse effects.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2514637"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144319101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of fire needle therapy combined with 308-nm excimer laser treatment in patients with stable acral vitiligo: a retrospective cohort study. 火针联合308 nm准分子激光治疗稳定性肢端白癜风的疗效和安全性：一项回顾性队列研究。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-07-04 DOI: 10.1080/09546634.2025.2527808

Hui Wang, Ninggang Chen, Jingjing Ye, Lian Zhang

{"title":"Efficacy and safety of fire needle therapy combined with 308-nm excimer laser treatment in patients with stable acral vitiligo: a retrospective cohort study.","authors":"Hui Wang, Ninggang Chen, Jingjing Ye, Lian Zhang","doi":"10.1080/09546634.2025.2527808","DOIUrl":"https://doi.org/10.1080/09546634.2025.2527808","url":null,"abstract":"Objective: To investigate the efficacy and safety of 308-nm excimer laser therapy with or without fire needle therapy in patients with stable acral vitiligo.Methods: A retrospective study was conducted to review patients with stable acral vitiligo treated between January 2020 and October 2024. In addition to topical halometasone cream, patients received either 308-nm excimer laser therapy alone (laser group) or a combination of 308-nm excimer laser and fire needle therapies (combination group) for three months. Vitiligo Area Scoring Index (VASI), physician global assessment (PGA), pain during treatment, and side effects were compared between the groups.Results: A total of 62 patients (32 in the laser group and 30 in the combination group.) were included. The mean age was 34.2 ± 9.8 years, with 39 (62.9%) males. Baseline characteristics were comparable between the two groups. Patients in both groups experienced a reduction in VASI scores (0.06 ± 0.74 and 0.16 ± 0.14 in the laser and combination groups, respectively). Compared with the laser group, the combination group showed significant improvement in lesion appearance, but reported mild pain (p < 0.001). Both groups experienced mild skin reactions, which resolved quickly after treatment.Conclusions: Combination therapy with 308-nm excimer laser and fire needle is a safe and effective approach for stable acral vitiligo.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2527808"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Burden of chronic spontaneous urticaria relative to atopic dermatitis and psoriasis in the United States. 在美国，慢性自发性荨麻疹的负担与特应性皮炎和牛皮癣有关。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-24 DOI: 10.1080/09546634.2025.2517384

Weily Soong, Dhaval Patil, Jonathan Rodrigues, Ravneet K Kohli, Kathryn Krupsky, Shaloo Gupta, Bridget L Balkaran, Maria-Magdalena Balp

{"title":"Burden of chronic spontaneous urticaria relative to atopic dermatitis and psoriasis in the United States.","authors":"Weily Soong, Dhaval Patil, Jonathan Rodrigues, Ravneet K Kohli, Kathryn Krupsky, Shaloo Gupta, Bridget L Balkaran, Maria-Magdalena Balp","doi":"10.1080/09546634.2025.2517384","DOIUrl":"https://doi.org/10.1080/09546634.2025.2517384","url":null,"abstract":"Purpose: To evaluate the burden of chronic spontaneous urticaria (CSU) compared with atopic dermatitis (AD) and psoriasis (PSO).Methods: This retrospective, cross-sectional study used real-world data from adult respondents from the 2019 US National Health and Wellness Survey (NHWS). Outcome measures included the 36-item Short-Form Survey version 2 (SF-36v2; mental and physical component summary [MCS and PCS] scores), Work Productivity and Activity Impairment (WPAI), and healthcare resource utilization (HCRU).Results: Among 74,994 respondents (CSU N = 371; AD N = 549; PSO N = 2061), mean (standard deviation [SD]) age at data collection was 41.7 (14.0), 48.4 (16.3), and 51.4 (16.6) years for CSU, AD, and PSO, respectively. Mean (standard error [SE]) MCS and PCS scores were lower (worse) among respondents with physician-diagnosed CSU vs. AD and PSO, respectively: MCS: 41.3 (0.6) vs. 44.8 (0.5) vs. 45.3 (0.2); PCS: 42.1 (0.5) vs. 47.8 (0.4) vs. 47.7 (0.2); all p < 0.001. Respondents with CSU reported higher (p < 0.001) work and activity impairment and HCRU vs. respondents with AD or PSO.Conclusion: After adjusting for confounders, respondents with CSU experienced higher humanistic and economic burden compared with respondents with AD or PSO, indicating a need for new treatments and improved clinical management.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2517384"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144487584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PCSK9 is upregulated and correlated with more severe disease condition but fails to predict treatment outcomes in psoriasis patients. PCSK9上调并与更严重的疾病状况相关，但不能预测银屑病患者的治疗结果。

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-06-04 DOI: 10.1080/09546634.2025.2482867

Xuwen Yin, Lei Shi, Ni Zhang, Heng Li, Jianwen Long, Xinjian Yu

{"title":"PCSK9 is upregulated and correlated with more severe disease condition but fails to predict treatment outcomes in psoriasis patients.","authors":"Xuwen Yin, Lei Shi, Ni Zhang, Heng Li, Jianwen Long, Xinjian Yu","doi":"10.1080/09546634.2025.2482867","DOIUrl":"https://doi.org/10.1080/09546634.2025.2482867","url":null,"abstract":"Background: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) not only regulates cholesterol metabolism and cardiovascular disorder but also modifies inflammatory response and autoimmunity.Objective: This study investigated the relation of PCSK9 to clinical features and treatment outcomes in psoriasis patients.Methods: One hundred and five psoriasis patients who initiated systemic treatment due to moderate-to-severe disease condition were enrolled. Baseline characteristics and treatment response after 12-week treatment were collected. Their serum samples before treatment initiation were collected and sent to PCSK9 detection by enzyme-linked immunosorbent assay. Serum PCSK9 was also detected in 30 healthy subjects.Results: PCSK9 level was 2-fold times in psoriasis patients vs. healthy subjects. PCSK9 could predict psoriasis risk with AUC of 0.777. By optimum cutoff value of 179 ng/ml, PCSK9 had the best predictive potential for psoriasis risk. PCSK9 quartile was positively correlated with BMI, hyperlipemia history, PASI, and sPGA. However, PCSK9 quartile was not correlated with PASI 75 response, PASI 90 response, or sPGA 0/1 response at week 12.Conclusion: PCSK9 is upregulated and correlated with severe disease condition, but fails to predict treatment outcomes in psoriasis patients.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2482867"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial. 伊瓦马替尼治疗中重度特应性皮炎患者的疗效和安全性：一项III期试验的事后分析

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-11-25 DOI: 10.1080/09546634.2025.2591478

Qingchun Diao, Ruiling Jia, Min Li, Peng Zhao, Fang Lu, Qin Zhang, Chunzhu Ning, Juan Long, Jiajia Li, Yan Huang, Yuyi Wang

{"title":"Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.","authors":"Qingchun Diao, Ruiling Jia, Min Li, Peng Zhao, Fang Lu, Qin Zhang, Chunzhu Ning, Juan Long, Jiajia Li, Yan Huang, Yuyi Wang","doi":"10.1080/09546634.2025.2591478","DOIUrl":"10.1080/09546634.2025.2591478","url":null,"abstract":"Background: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).Objective: This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments.Methods: This was a post-hoc analysis of a phase III clinical trial of Ivarmacitinib in moderate-to-severe AD (NCT04875169). Subgroup analysis by with (N = 132) or without (N = 204) previous systemic treatments (systemic corticosteroids, biologics, or other immunomodulators) was performed.Results: In patients with previous systemic treatments, Ivarmacitinib 8 mg (n = 34) and 4 mg (n = 53) exhibited higher Investigator Global Assessment (IGA), Eczema Area and Severity Index (EASI)-75, EASI-90, and Worst Itch Numeric Rating Scale (WI-NRS) 4 response rates, and a greater reduction in Dermatology Life Quality Index (DLQI) score compared with placebo (n = 45) at most timepoints from W4 to W16. In patients without previous systemic treatments, these outcomes were notably increased in Ivarmacitinib 8 mg (n = 78) and 4 mg (n = 60) versus placebo (n = 66) throughout W4 to W16. The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments.Conclusion: Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2591478"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145607781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical efficacy of platelet-rich fibrin in chronic wound healing: a retrospective study. 富血小板纤维蛋白在慢性伤口愈合中的临床疗效回顾性研究。

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-12-09 DOI: 10.1080/09546634.2025.2598185

Zhou Lin, Yanping Zhang, Liqin Fu, Weifeng Lan, Yuqing Wen

{"title":"Clinical efficacy of platelet-rich fibrin in chronic wound healing: a retrospective study.","authors":"Zhou Lin, Yanping Zhang, Liqin Fu, Weifeng Lan, Yuqing Wen","doi":"10.1080/09546634.2025.2598185","DOIUrl":"https://doi.org/10.1080/09546634.2025.2598185","url":null,"abstract":"Objective: This retrospective cohort study evaluated the clinical effectiveness of platelet-rich fibrin (PRF) versus conventional therapy in chronic wound management.Methods: Electronic health records from a single institution (2010-2020) were analyzed. Included patients were adults (≥18 years) diagnosed with a chronic wound and treated with either PRF or conventional therapy.Results: Wound healing was faster in the PRF group (36.2 ± 9.3 days vs. 60.4 ± 11.4 days, p < .001). Multivariate Cox regression identified PRF as an independent factor for accelerated healing (HR = 0.61, 95% CI: 0.52-0.72, p = .001). Wound closure (89.8% vs. 70.6%, p < .001) and complete re-epithelialization (90.3% vs. 69.6%, p < .001) were higher in the PRF group. Wound recurrence (10.1% vs. 25.1%, p = .029) and scar formation (12.4% vs. 28.7%, p = .008) were lower in the PRF group. The incidence of adverse events was similar between groups (8.7% vs. 10.4%, p = .582).Conclusion: PRF therapy accelerates chronic wound healing, improves healing quality by reducing recurrence and scarring, and demonstrates a safety profile comparable to conventional care.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2598185"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145717252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world outcomes of dupilumab therapy in moderate-to-severe atopic dermatitis patients: an observational retrospective study in Gulf countries. dupilumab治疗中重度特应性皮炎患者的实际结果：海湾国家的一项观察性回顾性研究

IF 3.9

The Journal of dermatological treatment Pub Date : 2025-12-01 Epub Date: 2025-11-06 DOI: 10.1080/09546634.2025.2572650

Yousef Binamer, Amani AlFalasi, Mohammed Alajlan, Waqas S Abdulwahhab, Fatima BinSayyar, Zubair Wani, Shubhada Bichu, Duaa Gadalla, Monira Abdullah Alnasser, Ghada Elmorshidy, Ahmed Barakat, Sahar Chmayse, Mohammed Hafiz, Zahir Chouikrat, Dina Jabaji, Monica Fahmy

{"title":"Real-world outcomes of dupilumab therapy in moderate-to-severe atopic dermatitis patients: an observational retrospective study in Gulf countries.","authors":"Yousef Binamer, Amani AlFalasi, Mohammed Alajlan, Waqas S Abdulwahhab, Fatima BinSayyar, Zubair Wani, Shubhada Bichu, Duaa Gadalla, Monira Abdullah Alnasser, Ghada Elmorshidy, Ahmed Barakat, Sahar Chmayse, Mohammed Hafiz, Zahir Chouikrat, Dina Jabaji, Monica Fahmy","doi":"10.1080/09546634.2025.2572650","DOIUrl":"10.1080/09546634.2025.2572650","url":null,"abstract":"Objectives: Dupilumab has demonstrated strong efficacy and safety in clinical trials for atopic dermatitis (AD), but real-world data from the Greater Gulf region remain limited. This study aimed to evaluate the real-world effectiveness and safety of dupilumab in adolescents and adults with moderate-to-severe AD in Saudi Arabia and the United Arab Emirates.Methods: A retrospective observational study was conducted in adolescents and adults (≥12 years) with moderate-to-severe AD, who had received dupilumab for one to three years. Clinical outcomes were assessed using SCORing Atopic Dermatitis (SCORAD) and the Dermatology Life Quality Index (DLQI), while safety was evaluated through reported adverse events (AEs).Results: Ninety-five patients were eligible, with a mean age of 29.3 years, and 52.6% were males. The mean baseline SCORAD score was 49.9, which decreased markedly to 21.5 after one month, 12.7 after three months, and 14.1 at six months. At six months, data were available for 71 patients, of whom 76% achieved SCORAD-50 and 52.1% achieved SCORAD-75. Reported AEs were generally mild, the most frequent being dry eyes (14.7%), dry eyes with pruritus (8.4%), and facial erythema (6.3%). No serious AEs or treatment discontinuations were recorded.Conclusion: Dupilumab demonstrated sustained clinical improvements and favorable safety. These findings reinforce the results of previous real-world studies and Randomized Controlled Trials.","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"36 1","pages":"2572650"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145454391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0